Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7771950 versus tucatinib with trastuzumab + capecitabine in pretreated HER2-positive advanced or metastatic breast cancer
PACTR202605565481660Phase 2Not yet recruiting
- Sponsor
- Roche
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of RO7771950, tucatinib, trastuzumab and capecitabine in breast cancer (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival in the full analysis set. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on PACTR202605565481660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202605565481660.